Jason Andrade
@drjasonandrade.bsky.social
Director of Cardiac Electrophysiology VGH / Clinical Faculty UBC / Co-Chair CCS AF Guidelines / CHRS Device Chair
On behalf of the Canadian Heart Rhythm Society Device Advisory Committee, please find attached the Canadian Guidance for the 2025 Boston Scientific RELIANCE ePTFE ICD lead advisory.
July 29, 2025 at 1:29 PM
On behalf of the Canadian Heart Rhythm Society Device Advisory Committee, please find attached the Canadian Guidance for the 2025 Boston Scientific RELIANCE ePTFE ICD lead advisory.
If you’re free come learn how AI can enable clinical trials by providing expert adjudication of arrhythmia outcomes
E.g. 1 year of follow-up in CIRCA-DOSE generated 32000 arrhythmia events needing 80k adjudications, which is labour intensive.
AI is poised to be transformative
E.g. 1 year of follow-up in CIRCA-DOSE generated 32000 arrhythmia events needing 80k adjudications, which is labour intensive.
AI is poised to be transformative
April 25, 2025 at 11:02 PM
If you’re free come learn how AI can enable clinical trials by providing expert adjudication of arrhythmia outcomes
E.g. 1 year of follow-up in CIRCA-DOSE generated 32000 arrhythmia events needing 80k adjudications, which is labour intensive.
AI is poised to be transformative
E.g. 1 year of follow-up in CIRCA-DOSE generated 32000 arrhythmia events needing 80k adjudications, which is labour intensive.
AI is poised to be transformative
It’s amazing to see consistent information across populations
Recapitulating data from CIRCA-DOSE the recent Advantage AF showed AF burden <0.1% & AF episodes less <1h on follow-up had HCU comparable to no AF
Same threshold paroxysmal and Persistent AF
shorturl.at/gBxXb
Recapitulating data from CIRCA-DOSE the recent Advantage AF showed AF burden <0.1% & AF episodes less <1h on follow-up had HCU comparable to no AF
Same threshold paroxysmal and Persistent AF
shorturl.at/gBxXb
April 25, 2025 at 3:31 AM
It’s amazing to see consistent information across populations
Recapitulating data from CIRCA-DOSE the recent Advantage AF showed AF burden <0.1% & AF episodes less <1h on follow-up had HCU comparable to no AF
Same threshold paroxysmal and Persistent AF
shorturl.at/gBxXb
Recapitulating data from CIRCA-DOSE the recent Advantage AF showed AF burden <0.1% & AF episodes less <1h on follow-up had HCU comparable to no AF
Same threshold paroxysmal and Persistent AF
shorturl.at/gBxXb
And with that my time at #EHRA2025 and the Ablation innovation summit comes to a close. Congratulations to the organisers for curating another amazing meeting, and for facilitating such a wonderful knowledge exchange
April 1, 2025 at 10:47 AM
And with that my time at #EHRA2025 and the Ablation innovation summit comes to a close. Congratulations to the organisers for curating another amazing meeting, and for facilitating such a wonderful knowledge exchange
March 30, 2025 at 7:52 AM
The shorter blanking will enable earlier intervention to improve clinical outcomes (eg, early reablation) at the expense of potentially overtreating a minority of patients (4%) with a low burden of AF.
www.ahajournals.org/doi/10.1161/...
www.ahajournals.org/doi/10.1161/...
February 20, 2025 at 4:19 PM
The shorter blanking will enable earlier intervention to improve clinical outcomes (eg, early reablation) at the expense of potentially overtreating a minority of patients (4%) with a low burden of AF.
www.ahajournals.org/doi/10.1161/...
www.ahajournals.org/doi/10.1161/...
Perhaps more interesting is the observation that failure timing and burden were interrelated.
Those who failed earlier (e.g. month 3) had nearly 20x higher burden than those that failed later (after month 3).
Those who failed earlier (e.g. month 3) had nearly 20x higher burden than those that failed later (after month 3).
February 20, 2025 at 4:19 PM
Perhaps more interesting is the observation that failure timing and burden were interrelated.
Those who failed earlier (e.g. month 3) had nearly 20x higher burden than those that failed later (after month 3).
Those who failed earlier (e.g. month 3) had nearly 20x higher burden than those that failed later (after month 3).
We found:
1. A shorter blanking period lowered the one-year freedom from atrial tachyarrhythmia to 49.6% (8 week blanking) from 53.7% (12 week blanking), but
2. The median AF burden in patients with arrhythmia recurrence did not differ between an 8- and 12-week blanking period (0.18% vs 0.23%).
1. A shorter blanking period lowered the one-year freedom from atrial tachyarrhythmia to 49.6% (8 week blanking) from 53.7% (12 week blanking), but
2. The median AF burden in patients with arrhythmia recurrence did not differ between an 8- and 12-week blanking period (0.18% vs 0.23%).
February 20, 2025 at 4:19 PM
We found:
1. A shorter blanking period lowered the one-year freedom from atrial tachyarrhythmia to 49.6% (8 week blanking) from 53.7% (12 week blanking), but
2. The median AF burden in patients with arrhythmia recurrence did not differ between an 8- and 12-week blanking period (0.18% vs 0.23%).
1. A shorter blanking period lowered the one-year freedom from atrial tachyarrhythmia to 49.6% (8 week blanking) from 53.7% (12 week blanking), but
2. The median AF burden in patients with arrhythmia recurrence did not differ between an 8- and 12-week blanking period (0.18% vs 0.23%).
Remarkably these trials show a very consistent result, catheter ablation was associated with a 85% reduction in the rate of progression to more advanced forms of AF (eg persistent AF).
Meaning we now have an intervention that is disease modifying.
www.heartrhythmjournal.com/article/S154...
Meaning we now have an intervention that is disease modifying.
www.heartrhythmjournal.com/article/S154...
January 7, 2025 at 2:51 PM
Remarkably these trials show a very consistent result, catheter ablation was associated with a 85% reduction in the rate of progression to more advanced forms of AF (eg persistent AF).
Meaning we now have an intervention that is disease modifying.
www.heartrhythmjournal.com/article/S154...
Meaning we now have an intervention that is disease modifying.
www.heartrhythmjournal.com/article/S154...
But observational evidence doesn't tell us about treatment effects, so the issue remained unresolved until recently
In the past few years we have seen 5 RCTs compare pharmacotherapy to catheter ablation as a first, second, or third line therapy
www.nejm.org/doi/full/10....
In the past few years we have seen 5 RCTs compare pharmacotherapy to catheter ablation as a first, second, or third line therapy
www.nejm.org/doi/full/10....
January 7, 2025 at 2:51 PM
But observational evidence doesn't tell us about treatment effects, so the issue remained unresolved until recently
In the past few years we have seen 5 RCTs compare pharmacotherapy to catheter ablation as a first, second, or third line therapy
www.nejm.org/doi/full/10....
In the past few years we have seen 5 RCTs compare pharmacotherapy to catheter ablation as a first, second, or third line therapy
www.nejm.org/doi/full/10....
But studies (and clinical management) tends to focus merely on the recurrence of arrhythmia, often not considering that our interventions can be disease modifying.
For example, observational evidence suggested progression was greatest in those treated with rate control…
For example, observational evidence suggested progression was greatest in those treated with rate control…
January 7, 2025 at 2:51 PM
But studies (and clinical management) tends to focus merely on the recurrence of arrhythmia, often not considering that our interventions can be disease modifying.
For example, observational evidence suggested progression was greatest in those treated with rate control…
For example, observational evidence suggested progression was greatest in those treated with rate control…
Atrial Fibrillation is a chronic and progressive disease, with progression being associated with worse clinical outcomes.
www.heartrhythmjournal.com/article/S154...
www.heartrhythmjournal.com/article/S154...
January 7, 2025 at 2:51 PM
Atrial Fibrillation is a chronic and progressive disease, with progression being associated with worse clinical outcomes.
www.heartrhythmjournal.com/article/S154...
www.heartrhythmjournal.com/article/S154...
We had a great weekend in Washington at the TransformAf meeting followed by the Cardiovascular Clinical Trialists Forum.
The former presenting the landscape of pulsed field ablation, from lesion science to clinical efficacy.
The latter bringing together clinical trialists across 🫀, 🧠, 💉, etc
The former presenting the landscape of pulsed field ablation, from lesion science to clinical efficacy.
The latter bringing together clinical trialists across 🫀, 🧠, 💉, etc
December 11, 2024 at 7:50 PM
We had a great weekend in Washington at the TransformAf meeting followed by the Cardiovascular Clinical Trialists Forum.
The former presenting the landscape of pulsed field ablation, from lesion science to clinical efficacy.
The latter bringing together clinical trialists across 🫀, 🧠, 💉, etc
The former presenting the landscape of pulsed field ablation, from lesion science to clinical efficacy.
The latter bringing together clinical trialists across 🫀, 🧠, 💉, etc
Celebrating John A. Cairns on his appointment to the Order of Canada. In addition to major international contributions to cardiology, notably demonstrating the benefits of aspirin for patients with unstable angina, John has been a support and mentor to many within and outside our division.
November 24, 2024 at 4:57 AM
Celebrating John A. Cairns on his appointment to the Order of Canada. In addition to major international contributions to cardiology, notably demonstrating the benefits of aspirin for patients with unstable angina, John has been a support and mentor to many within and outside our division.
There’s something special about terminating AVNRT with ablation.
Personally I like to target the slow pathway in tachycardia (1), watching it slow (2) with early temperature drop then blocks in slow pathway (3).
Personally I like to target the slow pathway in tachycardia (1), watching it slow (2) with early temperature drop then blocks in slow pathway (3).
November 23, 2024 at 4:13 PM
There’s something special about terminating AVNRT with ablation.
Personally I like to target the slow pathway in tachycardia (1), watching it slow (2) with early temperature drop then blocks in slow pathway (3).
Personally I like to target the slow pathway in tachycardia (1), watching it slow (2) with early temperature drop then blocks in slow pathway (3).
Would you call this atrial fibrillation?
What’s the prognostic significance of this finding?
What’s the prognostic significance of this finding?
November 20, 2024 at 5:48 AM
Would you call this atrial fibrillation?
What’s the prognostic significance of this finding?
What’s the prognostic significance of this finding?
Congrats to Rajeev Pathak, @prashsanders.bsky.social and team on the ARREST-AF RCT.
Incredibly informative data - adjective comprehensive risk factor optimisation significantly improved post ablation AF freedom.
We now have RCT evidence supporting RFM as a foundation and pillar of AF management.
Incredibly informative data - adjective comprehensive risk factor optimisation significantly improved post ablation AF freedom.
We now have RCT evidence supporting RFM as a foundation and pillar of AF management.
November 18, 2024 at 8:09 PM
Congrats to Rajeev Pathak, @prashsanders.bsky.social and team on the ARREST-AF RCT.
Incredibly informative data - adjective comprehensive risk factor optimisation significantly improved post ablation AF freedom.
We now have RCT evidence supporting RFM as a foundation and pillar of AF management.
Incredibly informative data - adjective comprehensive risk factor optimisation significantly improved post ablation AF freedom.
We now have RCT evidence supporting RFM as a foundation and pillar of AF management.
Fantastic presentation from Mina Chung on the results of the TRIM-AF study.
RFM +/- Metformin had benefit in symptoms but no benefit on AF burden.
RFM +/- Metformin had benefit in symptoms but no benefit on AF burden.
November 18, 2024 at 4:35 PM
Fantastic presentation from Mina Chung on the results of the TRIM-AF study.
RFM +/- Metformin had benefit in symptoms but no benefit on AF burden.
RFM +/- Metformin had benefit in symptoms but no benefit on AF burden.
Congratulations to Lena Rivard on the @ahascience.bsky.social presentation of the BRAIN-AF study results.
Major observation is that cognitive decline occurs in many « low risk » AF patients.
Unfortunately, Rivaroxaban 15 mg daily did not impact this risk in this double-dummy RCT.
Major observation is that cognitive decline occurs in many « low risk » AF patients.
Unfortunately, Rivaroxaban 15 mg daily did not impact this risk in this double-dummy RCT.
November 16, 2024 at 8:24 PM
Congratulations to Lena Rivard on the @ahascience.bsky.social presentation of the BRAIN-AF study results.
Major observation is that cognitive decline occurs in many « low risk » AF patients.
Unfortunately, Rivaroxaban 15 mg daily did not impact this risk in this double-dummy RCT.
Major observation is that cognitive decline occurs in many « low risk » AF patients.
Unfortunately, Rivaroxaban 15 mg daily did not impact this risk in this double-dummy RCT.
Congratulations to @johnlsapp on the presentation and publication of VANISH-2.
First line VT ablation is associated with significant reduction in composite of death, VT, storm for patients with ischemic cardiomyopathy.
www.nejm.org/doi/full/10....
First line VT ablation is associated with significant reduction in composite of death, VT, storm for patients with ischemic cardiomyopathy.
www.nejm.org/doi/full/10....
November 16, 2024 at 7:50 PM
Congratulations to @johnlsapp on the presentation and publication of VANISH-2.
First line VT ablation is associated with significant reduction in composite of death, VT, storm for patients with ischemic cardiomyopathy.
www.nejm.org/doi/full/10....
First line VT ablation is associated with significant reduction in composite of death, VT, storm for patients with ischemic cardiomyopathy.
www.nejm.org/doi/full/10....
An #AHA24 Pre-LBCT session 2 selfie with two PIs
- Léna Rivard from @ICMtl presenting the results from BRAIN-AF, and
- John Sapp from @DalhousieU presenting the results from VANISH-2
- Léna Rivard from @ICMtl presenting the results from BRAIN-AF, and
- John Sapp from @DalhousieU presenting the results from VANISH-2
November 16, 2024 at 7:16 PM
An #AHA24 Pre-LBCT session 2 selfie with two PIs
- Léna Rivard from @ICMtl presenting the results from BRAIN-AF, and
- John Sapp from @DalhousieU presenting the results from VANISH-2
- Léna Rivard from @ICMtl presenting the results from BRAIN-AF, and
- John Sapp from @DalhousieU presenting the results from VANISH-2
Please join us in Main Event II at 15:15 for « Fellowship of the Ring: Atrial Fibrillation & Heart Failure, a Collaborative Journey Through the New Middle Earth »
November 16, 2024 at 6:16 PM
Please join us in Main Event II at 15:15 for « Fellowship of the Ring: Atrial Fibrillation & Heart Failure, a Collaborative Journey Through the New Middle Earth »
However, two of his brothers (my Great uncles) weren’t so lucky.
Maurice, a Private in the Royal Regiment of Artillery was killed in Western Europe (age 21).
His brother Oswald, a Gunner in Royal Artillery, 7th medium regiment was killed in Greece (age 19, memorialised in Athens).
Maurice, a Private in the Royal Regiment of Artillery was killed in Western Europe (age 21).
His brother Oswald, a Gunner in Royal Artillery, 7th medium regiment was killed in Greece (age 19, memorialised in Athens).
November 12, 2024 at 12:20 AM
However, two of his brothers (my Great uncles) weren’t so lucky.
Maurice, a Private in the Royal Regiment of Artillery was killed in Western Europe (age 21).
His brother Oswald, a Gunner in Royal Artillery, 7th medium regiment was killed in Greece (age 19, memorialised in Athens).
Maurice, a Private in the Royal Regiment of Artillery was killed in Western Europe (age 21).
His brother Oswald, a Gunner in Royal Artillery, 7th medium regiment was killed in Greece (age 19, memorialised in Athens).
Herbert, my grandfather, was in the King’s Squad of the Royal Marines, serving on the HMS Hood until it was sunk by the Bismark in May 1941.
All but 3 of the 1,418 crew died in the Battle of the Denmark Strait.
My grandfather avoided that fate as he was on shore
leave marrying my grandmother.
All but 3 of the 1,418 crew died in the Battle of the Denmark Strait.
My grandfather avoided that fate as he was on shore
leave marrying my grandmother.
November 12, 2024 at 12:20 AM
Herbert, my grandfather, was in the King’s Squad of the Royal Marines, serving on the HMS Hood until it was sunk by the Bismark in May 1941.
All but 3 of the 1,418 crew died in the Battle of the Denmark Strait.
My grandfather avoided that fate as he was on shore
leave marrying my grandmother.
All but 3 of the 1,418 crew died in the Battle of the Denmark Strait.
My grandfather avoided that fate as he was on shore
leave marrying my grandmother.
My Great Grand Father, Arthur Edward, was a private in the Royal Fusiliers, fighting in
Western France during World War One.
He survived the conflict, returning to England where he married and raised seven children.
Western France during World War One.
He survived the conflict, returning to England where he married and raised seven children.
November 12, 2024 at 12:20 AM
My Great Grand Father, Arthur Edward, was a private in the Royal Fusiliers, fighting in
Western France during World War One.
He survived the conflict, returning to England where he married and raised seven children.
Western France during World War One.
He survived the conflict, returning to England where he married and raised seven children.